Glenmark Pharmaceuticals rose 3% after its subsidiary Ichnos Glenmark Innovation secured a $700 million (₹6,160 crore) upfront payment from AbbVie under a global licensing deal for ISB 2001. The deal strengthens Glenmark's finances, reduces debt, and accelerates drug development, highlighting its strong R&D potential.